{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T17:44:52Z","timestamp":1770831892673,"version":"3.50.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1007\/s00210-023-02803-z","type":"journal-article","created":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T08:02:31Z","timestamp":1698825751000},"page":"3239-3246","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Pharmacological hyperprolactinemia: a retrospective analysis of 501 hyperprolactinemia cases in primary care setting"],"prefix":"10.1007","volume":"397","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2973-5436","authenticated-orcid":false,"given":"Ana M.","family":"Garc\u00eda Cano","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Rosillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"G\u00f3mez Lozano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luc\u00eda","family":"Jim\u00e9nez Mendiguch\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"March\u00e1n Pinedo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Argeme","family":"Rodr\u00edguez Torres","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0519-0072","authenticated-orcid":false,"given":"Marta","family":"Araujo-Castro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,11,1]]},"reference":[{"key":"2803_CR1","doi-asserted-by":"crossref","unstructured":"Alvarez-Tutor E, Forga-LLenas L, Rodriguez-Erdozain R, Go\u00f1i-Iriarte MJ, Menendez-Torre E, Alvarez-Tutor J. Persistent increase of PRL after oral contraceptive treatment. Arch Gynecol Obstet. 13 de diciembre de 1999; 263(1-2):45-50","DOI":"10.1007\/s004040050261"},{"issue":"1","key":"2803_CR2","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.encep.2012.03.002","volume":"40","author":"I Besnard","year":"2014","unstructured":"Besnard I, Auclair V, Callery G, Gabriel-Bordenave C, Roberge C (2014) Hyperprolactin\u00e9mies induites par les antipsychotiques\u00a0: physiopathologie, clinique et surveillance. L\u2019Enc\u00e9phale. Febrero de 40(1):86\u201394","journal-title":"L\u2019Enc\u00e9phale. Febrero de"},{"issue":"6","key":"2803_CR3","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1097\/jcp.0b013e31815ac4e5","volume":"27","author":"M Byerly","year":"2007","unstructured":"Byerly M, Suppes T, Tran QV, Baker RA (2007) Clinical implications of antipsychotic-induced hyperprolactinemia in patients with schizophrenia spectrum or bipolar spectrum disorders: recent developments and current perspectives. J Clin Psychopharmacol. Diciembre de 27(6):639\u2013661","journal-title":"J Clin Psychopharmacol. Diciembre de"},{"key":"2803_CR4","unstructured":"Cano AM, Mendiguch\u00eda LJ, Coronado MR, Lozano AG, del Rey-Mej\u00edas \u00c1L, Merino MF, Pinedo MM, Araujo-Castro M. Causes of hyperprolactinaemia in the primary care setting: how to optimize hyperprolactinaemia management | Elsevier Enhanced Reader [Internet]. [citado 1 de junio de 2022]. Disponible en: https:\/\/reader.elsevier.com\/reader\/sd\/pii\/S2530016422001136?token=C164C4B3B7801502B4CDB27EC485D266A997B1C647495A70F4AAEE8DB82D3F45100C9DA4B00824A75D3A9BE3A83BD8C1&originRegion=eu-west-1&originCreation=20220601054604"},{"issue":"7","key":"2803_CR5","first-page":"506","volume":"31","author":"A Capozzi","year":"2015","unstructured":"Capozzi A, Scambia G, Pontecorvi A, Lello S (2015) Hyperprolactinemia: pathophysiology and therapeutic approach. Gynecol Endocrinol. 3 de julio de 31(7):506\u2013510","journal-title":"3 de julio de"},{"key":"2803_CR6","doi-asserted-by":"crossref","unstructured":"Coronel DA, De la Pe\u00f1a FR, Palacios-Cruz L, Cuevas D, Duran S (2022) Sociodemographic and clinical characteristics related with hyperprolactinaemia in psychiatric clinical population. Int J Psychiatry Clin Pract. 26 de abril de:1\u20138","DOI":"10.1080\/13651501.2022.2050259"},{"key":"2803_CR7","doi-asserted-by":"crossref","unstructured":"Druyts E, Zoratti MJ, Toor K, Wu P, Kanji S, Rabheru K, et al. Prolactin-related adverse events and change in prolactin levels in pediatric patients given antipsychotics for schizophrenia and schizophrenia spectrum disorders: a systematic review. BMC Pediatr. 9 de noviembre de 2016; 16:181","DOI":"10.1186\/s12887-016-0710-y"},{"issue":"2_suppl","key":"2803_CR8","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1177\/0269216307087148","volume":"22","author":"P Fitzgerald","year":"2008","unstructured":"Fitzgerald P, Dinan TG (2008) Prolactin and dopamine: what is the connection? A Review Article. J Psychopharmacol (Oxf). Marzo de 22(2_suppl):12\u201319","journal-title":"A Review Article. J Psychopharmacol (Oxf). Marzo de"},{"issue":"22","key":"2803_CR9","doi-asserted-by":"publisher","first-page":"3279","DOI":"10.1007\/s00213-017-4730-6","volume":"234","author":"J Grigg","year":"2017","unstructured":"Grigg J, Worsley R, Thew C, Gurvich C, Thomas N, Kulkarni J (2017) Antipsychotic-induced hyperprolactinemia: synthesis of world-wide guidelines and integrated recommendations for assessment, management and future research. Psychopharmacology (Berl). Noviembre de 234(22):3279\u20133297","journal-title":"Psychopharmacology (Berl). Noviembre de"},{"issue":"2","key":"2803_CR10","doi-asserted-by":"publisher","first-page":"e129","DOI":"10.18295\/squmj.2019.19.02.008","volume":"19","author":"AA Malik","year":"2019","unstructured":"Malik AA, Aziz F, Beshyah SA, Aldahmani KM (2019) Aetiologies of Hyperprolactinaemia: a retrospective analysis from a tertiary healthcare center. Sultan Qaboos Univ Med J. mayo de 19(2):e129\u2013e134","journal-title":"Sultan Qaboos Univ Med J. mayo de"},{"issue":"2","key":"2803_CR11","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1210\/jc.2010-1692","volume":"96","author":"S Melmed","year":"2011","unstructured":"Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA et al (2011) Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 1 de febrero de 96(2):273\u2013288","journal-title":"J Clin Endocrinol Metab. 1 de febrero de"},{"key":"2803_CR12","doi-asserted-by":"crossref","unstructured":"Milano W, Colletti C, Capasso A. Hyperprolactinemia induced by antipsychotics: from diagnosis to treatment approach. Endocr Metab Immune Disord - Drug Targets [Internet]. 23 de junio de 2017 [citado 29 de agosto de 2021]; 17(1). Disponible en: http:\/\/www.eurekaselect.com\/151824\/article","DOI":"10.2174\/1871530317666170424102332"},{"issue":"3","key":"2803_CR13","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.rpsm.2015.11.003","volume":"9","author":"\u00c1L Montejo","year":"2016","unstructured":"Montejo \u00c1L, Arango C, Bernardo M, Carrasco JL, Crespo-Facorro B, Cruz JJ et al (2016) Consenso espa\u00f1ol sobre los riesgos y detecci\u00f3n de la hiperprolactinemia iatrog\u00e9nica por antipsic\u00f3ticos. Rev Psiquiatr Salud Ment. Julio de 9(3):158\u2013173","journal-title":"Rev Psiquiatr Salud Ment. Julio de"},{"issue":"5","key":"2803_CR14","first-page":"421","volume":"28","author":"J Peuskens","year":"2014","unstructured":"Peuskens J, Pani L, Detraux J, De Hert M (2014) The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review. CNS Drugs. 28(5):421\u2013453","journal-title":"CNS Drugs."},{"issue":"2","key":"2803_CR15","first-page":"341","volume":"22","author":"VKB Prabhakar","year":"2008","unstructured":"Prabhakar VKB, Davis JRE, Hyperprolactinaemia. (2008) Best Pract Res Clin Obstet Gynaecol. Abril de 22(2):341\u2013353","journal-title":"Abril de"},{"issue":"1","key":"2803_CR16","first-page":"8","volume":"55","author":"JV Reyniak","year":"1980","unstructured":"Reyniak JV, Wenof M, Aubert JM, Stangel JJ (1980) Incidence of hyperprolactinemia during oral contraceptive therapy. Obstet Gynecol. Enero de 55(1):8\u201311","journal-title":"Obstet Gynecol. Enero de"},{"key":"2803_CR17","unstructured":"Rizzo LFL, Mana DL, Serra HA, Danilowicz K (2020) Hyperprolactinemia associated with psychiatric disorders.:11"},{"key":"2803_CR18","doi-asserted-by":"crossref","unstructured":"Ruljancic N, Bakliza A, VukPisk S, Geres N, Matic K, Ivezic E, et al. Antipsychotics-induced hyperprolactinemia and screening for macroprolactin. Biochem Medica [Internet]. 15 de febrero de 2021 [citado 8 de marzo de 2021]; 31(1). Disponible en: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC7745162\/","DOI":"10.11613\/BM.2021.010707"},{"issue":"12","key":"2803_CR19","first-page":"2203","volume":"8","author":"I Samperi","year":"2019","unstructured":"Samperi I, Lithgow K, Karavitaki N (2019) Hyperprolactinaemia. J Clin Med. 13 de diciembre de 8(12):2203","journal-title":"J Clin Med. 13 de diciembre de"},{"issue":"6","key":"2803_CR20","first-page":"575","volume":"169","author":"O Serri","year":"2003","unstructured":"Serri O, Chik CL, Ur E, Ezzat S (2003) Diagnosis and management of hyperprolactinemia. CMAJ Can Med Assoc J. 16 de septiembre de 169(6):575\u2013581","journal-title":"CMAJ Can Med Assoc J. 16 de septiembre de"},{"issue":"1","key":"2803_CR21","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1111\/cen.13156","volume":"86","author":"E Soto-Pedre","year":"2017","unstructured":"Soto-Pedre E, Newey PJ, Bevan JS, Greig N, Leese GP (2017) The epidemiology of hyperprolactinaemia over 20 years in the Tayside region of Scotland: the Prolactin Epidemiology, Audit and Research Study (PROLEARS). Clin Endocrinol (Oxf). 86(1):60\u201367","journal-title":"Clin Endocrinol (Oxf)."},{"key":"2803_CR22","unstructured":"Technical Library | Abbott Core Laboratory [Internet]. [citado 1 de julio de 2021]. Disponible en: https:\/\/www.corelaboratory.abbott\/tl\/ous\/technical-library.html"},{"issue":"4","key":"2803_CR23","first-page":"185","volume":"6","author":"A Tewksbury","year":"2016","unstructured":"Tewksbury A, Olander A (2016) Management of antipsychotic-induced hyperprolactinemia. Ment Health Clin. 29 de junio de 6(4):185\u2013190","journal-title":"Management of antipsychotic-induced hyperprolactinemia. Ment Health Clin. 29 de junio de"},{"issue":"1","key":"2803_CR24","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1590\/0004-2730000003002","volume":"58","author":"L Vilar","year":"2014","unstructured":"Vilar L, Fleseriu M, Bronstein MD (2014) Challenges and pitfalls in the diagnosis of hyperprolactinemia. Arq Bras Endocrinol Metabol. Febrero de 58(1):9\u201322","journal-title":"Arq Bras Endocrinol Metabol. Febrero de"},{"key":"2803_CR25","doi-asserted-by":"crossref","unstructured":"Yuen JWY, Kim DD, Procyshyn RM, Panenka WJ, Honer WG, Barr AM. A focused review of the metabolic side-effects of clozapine. Front Endocrinol [Internet]. 25 de febrero de 2021 [citado 14 de abril de 2021]; 12. Disponible en: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC7947876\/","DOI":"10.3389\/fendo.2021.609240"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-023-02803-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-023-02803-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-023-02803-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T10:11:13Z","timestamp":1714990273000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-023-02803-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,1]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["2803"],"URL":"https:\/\/doi.org\/10.1007\/s00210-023-02803-z","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,1]]},"assertion":[{"value":"15 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed by the participants of the study were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The study was evaluated and approved by the Ethical committee of Hospital Ram\u00f3n y Cajal (approval date: 27\/04\/2021, ACTA 412).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The exemption of informed consent is requested, because it is a retrospective study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}